Circulating microRNAs and hypertension—from new insights into blood pressure regulation to biomarkers of cardiovascular risk

Romaine, Simon P. R.; Charchar, Fadi J.; Samani, Nilesh J.; Tomaszewski, Maciej

doi:10.1016/j.coph.2015.12.002

Cited by 50 publications

(51 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several animal and human studies indicate that miRNAs contribute to the regulation of these aforementioned mechanisms, representing a new promising potential target for therapies. Moreover, circulating miRNAs are emerging as effective biomarkers in essential hypertension as discussed more in depth below (150). …”

Section: Mirnas In Hypertensionmentioning

confidence: 99%

See 1 more Smart Citation

microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases

Lucia

Komici²,

Borghetti

et al. 2017

Front. Med.

View full text Add to dashboard Cite

Over the last decades, life expectancy has significantly increased although several chronic diseases persist in the population, with aging as the leading risk factor. Despite improvements in diagnosis and treatment, many elderlies suffer from cardiovascular problems that are much more frequent in an older, more fragile organism. In the long term, age-related cardiovascular diseases (CVDs) contribute to the decline of quality of life and ability to perform normal activities of daily living. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the posttranscriptional level in both physiological and pathological conditions. In this review, we will focus on the role of miRNAs in aging and age-related CVDs as heart failure, hypertension, atherosclerosis, atrial fibrillation, and diabetes mellitus. miRNAs are key regulators of complex biological mechanisms, representing an exciting potential therapeutic target in CVDs. Moreover, one major challenge in geriatric medicine is to find reliable biomarkers for diagnosis, prognosis, and prediction of the response to specific drugs. miRNAs represent a very promising tool due to their stability in the circulation and unique signature in CVDs. However, further studies are needed to investigate their translational potential in the real clinical practice.

show abstract

Section: Mirnas In Hypertensionmentioning

confidence: 99%

“…Different studies were performed using high-throughput methodology, like genome-wide array-based technique (150). Li et al compared miRNA expression level in 13 hypertensive and 5 control patients.…”

Section: Mirnas In Hypertensionmentioning

confidence: 99%

microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases

Lucia

Komici²,

Borghetti

et al. 2017

Front. Med.

View full text Add to dashboard Cite

show abstract

“…MicroRNAs are master regulators and can control the expression of a large number of genes. The same applies to other noncoding RNAs that may provide important insights into the pathogenesis of hypertension 26 . MicroRNAs are more stable in biological samples and can be extracted from blood and urine; there is general consensus that peripheral profiles from these substances provide at least some meaningful information about organ-specific expression 27 .…”

Section: Transcriptomicsmentioning

confidence: 99%

The Future of “Omics” in Hypertension

Currie

Delles

2017

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Despite decades of research and clinical practice, the pathogenesis of hypertension remains incompletely understood, and blood pressure is often suboptimally controlled. “Omics” technologies allow the description of a large number of molecular features and have the potential to identify new factors that contribute to blood pressure regulation and how they interact. In this review, we focus on the potential of genomics, transcriptomics, proteomics, and metabolomics and explore their roles in unraveling the pathophysiology and diagnosis of hypertension, the prediction of organ damage and treatment response, and monitoring treatment effect. Substantial progress has been made in the area of genomics, in which genome-wide association studies have identified > 50 blood pressure–related, single-nucleotide polymorphisms, and sequencing studies (especially in secondary forms of hypertension) have discovered novel regulatory pathways. In contrast, other omics technologies, despite their ability to provide detailed insights into the physiological state of an organism, have only more recently demonstrated their impact on hypertension research and clinical practice. The majority of current proteomic studies focus on organ damage resulting from hypertension and may have the potential to help us understand the link between blood pressure and organ failure but also serve as biomarkers for early detection of cerebrovascular or coronary disease. Examples include signatures for early detection of left ventricular dysfunction or albuminuria. Metabolomic studies have the potential to integrate environmental and intrinsic factors and are particularly suited to monitor the response to treatment. We discuss examples of omics studies in hypertension and explore the challenges related to these novel technologies.

show abstract

“…Though most closely studied in cancer, circulating miRNAs are of interest for several other diseases and disorders including pre-eclampsia [62], diabetes [63], cardiovascular disease [64] and hypertension [65], sepsis [66], inflammatory bowel disease [67], and even depression [68]. …”

Section: Liquid Biopsy: Technologies Advancing Personalized Medicinementioning

confidence: 99%

Technological advances in precision medicine and drug development

Maggi

Patterson

Montagna

2016

Expert Review of Precision Medicine and Drug Development

View full text Add to dashboard Cite

New technologies are rapidly becoming available to expand the arsenal of tools accessible for precision medicine and to support the development of new therapeutics. Advances in liquid biopsies, which analyze cells, DNA, RNA, proteins, or vesicles isolated from the blood, have gained particular interest for their uses in acquiring information reflecting the biology of tumors and metastatic tissues. Through advancements in DNA sequencing that have merged unprecedented accuracy with affordable cost, personalized treatments based on genetic variations are becoming a real possibility. Extraordinary progress has been achieved in the development of biological therapies aimed to even further advance personalized treatments. We provide a summary of current and future applications of blood based liquid biopsies and how new technologies are utilized for the development of biological therapeutic treatments. We discuss current and future sequencing methods with an emphasis on how technological advances will support the progress in the field of precision medicine.

show abstract

Circulating microRNAs and hypertension—from new insights into blood pressure regulation to biomarkers of cardiovascular risk

Abstract: Hypertension is a leading cause of cardiovascular morbidity and mortality worldwide, yet the molecular mechanisms underpinning the development of high blood pressure remain incompletely

Cited by 50 publications

References 29 publications

microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases

microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases

The Future of “Omics” in Hypertension

Technological advances in precision medicine and drug development

Contact Info

Product

Resources

About